The relationship of fibroblast growth factor 21 with cardiovascular outcome events in the Fenofibrate Intervention and Event Lowering in Diabetes study.

Ong, Kwok-Leung; Januszewski, Andrzej S; O'Connell, Rachel; Jenkins, Alicia J; Xu, Aimin; Sullivan, David R; Barter, Philip J; Hung, Wei-Ting; Scott, Russell S; Taskinen, Marja-Riitta; Keech, Anthony C; Rye, Kerry-Anne

Ong, Kwok-Leung; Januszewski, Andrzej S; O'Connell, Rachel; Jenkins, Alicia J; Xu, Aimin; Sullivan, David R; Barter, Philip J; Hung, Wei-Ting; Scott, Russell S; Taskinen, Marja-Riitta; Keech, Anthony C; Rye, Kerry-Anne.

Affiliation

Ong KL; Lipid Research Group, Heart Research Institute, Sydney, NSW, Australia, oklws@yahoo.com.hk.

Diabetologia ; 58(3): 464-73, 2015 Mar.

Article in En | MEDLINE | ID: mdl-25425220

Subject(s)

Diabetes Mellitus, Type 2/blood; Fenofibrate/therapeutic use; Fibroblast Growth Factors/blood; Hypolipidemic Agents/therapeutic use; Aged; Cardiovascular Diseases/blood; Diabetes Mellitus, Type 2/drug therapy; Enzyme-Linked Immunosorbent Assay; Female; Humans; Male; Middle Aged; Risk Factors; Stroke/blood

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Fenofibrate / Diabetes Mellitus, Type 2 / Fibroblast Growth Factors / Hypolipidemic Agents Type of study: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Diabetologia Year: 2015 Type: Article

Fulltext

XML

PubMed Links

Search on Google